Financial Tear Sheet

Corporate Profile


IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.

Primary IR Contact

Lynn Lewis or Leigh Salvo **Phone:** (415) 937-5404 **E-mail:** <u>investors@iridex.com</u>

Stock Performance

IRIX (Common Stock)					
Exchange	NASDAQ (US Dollar)				
Price	\$4.77				
Change (%)	▲ 0.16 (3.47%)				
Volume	13,212				
52 Week Low	\$3.72				
Market Cap	\$64,776,077				
Rolling EPS	-1.29				
PE Ratio	N/A				
Shares Outstanding	13,594,140				
Data as of 02/22/19 4:00 p.m. ET					



Recent Headlines & Events

02/12/19

IRIDEX Announces Resolution of its Dispute with Quantel Medical

01/08/19

IRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year

12/04/18

IRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance

There are currently no events scheduled.


Powered By EDGAROnline

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed

Analyst Estimates / Ratings

Mean Recommendation: 1.5



Unable to fulfill request.

SEC Filings

Filing Date	Form
02/19/19	SC 13D
02/14/19	SC 13G/A
02/14/19	SC 13G
02/12/19	8-K

Corporate Governance

William M. Moore President and CEO

Timothy D. Buckley Vice President, Marketing & North

American Sales

George Marcellino Vice President Clinical Affairs

Stacie Rodgers Vice President of Human Resources

Ownership Summary

Shareholders								
	Holders	Value (\$MM)	% O/S	Shares				
Institution	55	44.25	67.6	9,183,177				
Mutual Fund	34	9.99	15.5	2,103,856				
Insider *	10	15.70	13.6	1,845,068				

^{*}Insider values reflect direct beneficial ownership.

Top Holders								
	Shares Held	% O/S	Share Change	Filing Date				
Wasatch Advisors, Inc.	1,478,671	10.9	149,196	12/31/18				
Paragon JV Partners, LLC	1,320,000	9.7	0	12/31/18				
Acuta Capital Partners, LLC	1,174,500	8.6	-773,000	12/31/18				
Stanley Manne Trust	1,072,215	7.9	0	04/16/18				
BlueLine Partners, L.L.C.	999,802	7.4	17,060	02/19/19				
Moore (William M)	433,262	3.2	-4,432	01/24/19				
Renaissance Technologies LLC	363,800	2.7	28,300	12/31/18				
Driehaus Capital Management, LLC	280,000	2.1	0	12/31/18				
Brinker Capital Inc.	221,340	1.6	221,340	11/30/18				
Dimensional Fund Advisors, L.P.	207,148	1.5	7,404	12/31/18				